Minerva Neurosciences, Inc.
NERV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001598646
No open-market purchases or sales by Minerva Neurosciences, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $234.8M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Minerva Neurosciences, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 25 | 19 | −6 |
| Shares | 2.03M | 1.73M | −299.2K (−14.7%) |
| Value | $18.7M | $2.75M | −$16.0M (−85.3%) |
New holders (2)
Institutions that held Minerva Neurosciences, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Belpointe Asset Management LLC | 100 | $159 | 0.00% |
| Bank of America Corp | 6 | $10 | 0.00% |
Sold out (8)
Institutions that held Minerva Neurosciences, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Artal Group S.A. | 250,000 | $2.31M |
| FMR LLC | 28,272 | $261.0K |
| Point72 Asset Management, L.P. | 25,000 | $231.0K |
| Truist Financial Corp | 11,043 | $102.0K |
| Bank of Montreal | 10,000 | $97.0K |
| UBS Group AG | 5,732 | $53.0K |
| Lazard Asset Management LLC | 2,084 | $19.0K |
| Royal Bank of Canada | 1,181 | $11.0K |